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5 different samples, including a total of 659 borderline pa-
tients. Results: In all of the samples, a high correlation of the 
sum score was found between the BSL-23 and the BSL-95 
(range: 0.958–0.963). The internal consistency was high for 
both versions (BSL-23/Cronbach’s : 0.935–0.969; BSL-95/
Cronbach’s : 0.977–0.978). Both BSL-23 and BSL-95 clearly 
discriminated borderline personality disorder patients from 
patients with an axis I diagnosis (mean effect sizes were 1.13 
and 0.96 for the BSL-23 and BSL-95, respectively). In addition, 
comparisons before and after 3 months of dialectical behav-
ior therapy revealed a numerically larger effect size for the 
BSL-23 (d = 0.47) compared to the BSL-95 (d = 0.38). Conclu-
sion: The results indicate that the BSL-23 is an efficient and 
convenient self-rating instrument that displays good psy-
chometric properties comparable to those of the BSL-95. 
The BSL-23 also demonstrated sensitivity to the effects of 
therapy. Copyright © 2008 S. Karger AG, Basel
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Abstract
Background: The full version of the Borderline Symptom List 
(BSL; for clarification now labeled BSL-95) is a self-rating in-
strument for specific assessment of borderline-typical symp-
tomatology. The BSL-95 items are based on criteria of the 
DSM-IV, the revised version of the Diagnostic Interview for 
Borderline Personality Disorder, and the opinions of both 
clinical experts and borderline patients. The BSL-95 includes 
95 items. In order to reduce patient burden and assessment 
time, a short version with 23 items (BSL-23) was developed. 
Methods: The development of the BSL-23 was based on a 
sample of 379 borderline patients, considering the items 
from the BSL-95 that had the highest levels of sensitivity to 
change and the highest ability to discriminate borderline pa-
tients from other patient groups. In a second step, the psy-
chometric properties of the BSL-23 were investigated and 
compared with the psychometric properties of the BSL-95 in 
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Introduction
Borderline personality disorder (BPD) is a serious 
mental disorder, affecting approximately 1–2% of the 
general population [1, 2]. Patients with BPD suffer from 
a dysregulation of the affective system and show patterns 
of instability in several areas: affect regulation, impulse 
control, interpersonal relationships and self-image. Char-
acterized by significant psychosocial impairment [3] and 
a mortality rate by suicide of almost 10% [4], BPD patients 
are overrepresented among psychiatric in- and outpa-
tients [1], utilizing more mental health resources than 
most other psychiatric groups [5, 6].
In order to receive a diagnosis of BPD, an individual 
must meet 5 of the 9 DSM-IV [7] diagnostic criteria for 
BPD. Several clinician-administered diagnostic assess-
ment tools have been developed to assess severity and 
change in BPD symptoms, such as the ZAN-BPD [8], and 
the Borderline Disorder Severity Index [9], among others. 
Although these assessment methods have often demon-
strated strong psychometric properties, they require cli-
nician expertise for administration and interpretation. 
Valid self-report measures of BPD symptoms like the 
Borderline Symptom List (BSL) [10, 11], the Question-
naire of Thoughts and Feelings [12], the Personality Belief 
Questionnaire [13] and the Personality Disorder Beliefs 
Questionnaire [14] would facilitate the assessment of BPD 
symptoms in settings in which trained clinicians are not 
available, and would be useful for research on BPD as 
well.
The full version of the BSL (for clarification now la-
beled BSL-95) is a dimensional self-report measure spe-
cifically developed to quantify borderline symptomatol-
ogy [11]. The BSL-95 contains a list of 95 subjective com-
plaints and impairments often reported by borderline 
patients. These BSL items are based on criteria of the 
DSM-IV, the revised version of the Diagnostic Interview 
for BPD [15], and the opinions of both clinical experts 
and of BPD patients. The questionnaire uses a Likert-
type rating format (0 = ‘not at all’, 1 = ‘a little’, 2 = ‘rather’, 
3 = ‘much’, and 4 = ‘very strong’), asking the patient to 
evaluate the symptoms during the past week. One visual 
analog scale can be administered along with the 95 items, 
assessing the global well-being (range: 0 = ‘very bad’ to 
100 = ‘excellent’). The evaluation of the BSL-95 was based 
on data from a total of 478 BPD patients, 204 healthy con-
trols and 283 psychiatric patients with different axis I di-
agnoses [11]. The first unrotated factor accounted for 32% 
of the total variance among the items, and the internal 
consistency of the entire item set was high ( = 0.97), in-
dicating that a total score on the BSL-95 is an appropriate 
measure of overall severity of BPD symptoms. The total 
score is calculated by dividing the total sum by the num-
ber of valid items and ranges from 0.0 to 4.0. A factor 
analysis of the BSL-95 also revealed a 7-factor solution: 
self-perception, affect regulation, self-destruction, dys-
phoria, loneliness, intrusions and hostility.
Data showed that the BSL-95 has good psychometric 
properties [11]. In addition to high internal consistency, 
the test-retest reliability within 1 week was high (r = 
0.80, p ! 0.001). The BSL-95 demonstrated favorable 
convergent validity, with a moderate positive correlation 
with the 90-item revised Symptom Checklist (SCL-90-
R) [16], global severity index (a measure of overall psy-
chopathology), as well as moderate correlations with 
measures of anxiety. The BSL-95 was also negatively cor-
related with the visual analog scale we developed to mea-
sure global well-being (r = –0.74, p ! 0.001). Supporting 
the ability of the BSL-95 to discriminate groups, scores 
on this measure were significantly higher for BPD pa-
tients than for healthy controls or patients with other 
axis I diagnoses. The results did not reveal a particular 
influence of gender, age or level of education on the BSL-
95 scores. In addition, data suggest that scores on the 
BSL-95 are sensitive to therapeutic change in BPD symp-
toms. Patients with BPD (n = 63) demonstrated signifi-
cant reductions from pretreatment BSL-95 total scores 
after 3 months of inpatient Dialectical Behavior Therapy 
(DBT) [11]. It is well known that DBT leads to a signifi-
cant reduction of the Global Severity Index (GSI) score 
of the SCL-90-R.
Despite its strong psychometric properties, the BSL-95 
might be too long to be practical in some clinical settings. 
This is particularly true for treatment outcome studies, 
for which BPD symptoms constitute only one of many 
different variables of interest. Studies with multiple mea-
surement points require time-saving instruments. Thus, 
to reduce the patient burden and to increase researchers’ 
and clinicians’ willingness to use the BSL, a brief, uncom-
plicated, convenient measure would be beneficial. The 
current article describes the development of the short 
version of the BSL. The goal was to develop a brief version 
of the BSL-95 that retains good psychometric properties, 
is sensitive to change, and discriminates between BPD 
patients and other patient groups. We hypothesized that 
the BSL-23 would discriminate BPD patients from healthy 
controls and other psychiatric groups, and that the BSL-
23 would have positive correlations with measures of psy-
chopathology, depression and anxiety, and negative cor-
relations with a measure of global well-being. An addi-
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tional aim was to ensure that this brief measure is easy to 
administer and score; hence, we aimed to eliminate re-
verse-scored items as well. 
Methods
Subjects
The results reported in this article were based on 5 different 
samples with BPD patients (samples 1–4, 6) and 275 patients with 
different axis I diagnoses (samples 5a–5e). Samples 1–3 and sam-
ples 5a–5c were also used to develop and evaluate the full version 
of the BSL (BSL-95) [11]. Samples 4, 5d–5e and 6 are new and were 
evaluated for the first time in this study. In all samples, the pa-
tients were asked to fill out the BSL-95. Twenty-three items were 
then extracted from the BSL-95 to evaluate the short version 
(BSL-23) in samples 1–5e. Sample 6 completed the new BSL-23.
Sample 1
Analyses to develop the BSL-23 and initial analyses to evaluate 
the BSL-23 were based on a sample of 379 psychiatric in- and out-
patients (age: mean = 30.4 years, SD = 7.62; range 17–58) who met 
the DSM-IV criteria for BPD. The majority of the patients were 
female (81.1%). The subjects were recruited in 68 psychiatric hos-
pitals and 5 psychotherapeutic practices in Germany. Twenty-sev-
en percent met 5 DSM-IV criteria, 35% met 6 criteria, 22% met 7 
criteria, 11% met 8 criteria and 5% met 9 criteria. The interviews 
were carried out by trained and experienced clinicians. The BSL-
23 was derived from data collected using the BSL-95.
Sample 2
Analyses of the scale’s sensitivity to change were based on a 
sample of 63 female BPD patients (diagnosis based on the Struc-
tured Clinical Interview for DSM-IV Axis II Personality Disor-
ders [17]). Inpatients were recruited at 2 psychiatric hospitals in 
Germany, and 39 outpatients were recruited by therapists of the 
DBT Competency Network Darmstadt, Germany. Diagnostic in-
terviews were carried out by trained and experienced clinicians. 
The patients were asked to fill in the BSL-95 before and after a 3-
month treatment with DBT. There is strong empirical evidence 
that 3-month treatment with DBT leads to a significant reduction 
of the GSI score of the SCL-90-R [18, 19]. The BSL-23 was extract-
ed from data collected using the BSL-95.
Sample 3
To determine the test-retest reliability, the BSL-95 was admin-
istered a second time to 35 females in inpatient treatment experi-
encing BPD (diagnoses based on the Structured Clinical Inter-
view for DSM-IV Axis II Personality Disorders) [20] after an in-
terval of 7 days. The BSL-23 was extracted from data collected 
using the BSL-95.
Sample 4
Additional analyses to evaluate the BSL-23 were based on a 
sample of 147 female BPD patients: out of 390 female patients that 
were screened for the study, 155 patients met the criteria for BPD 
and fulfilled all inclusion (age 18–65, fluent German speaking, 
signing the informed consent form) and no exclusion criteria 
(history or current symptoms of a serious organic condition; 
schizophrenia, schizoaffective disorder or bipolar I disorder). The 
patients were referred to the Department of Psychiatry at the Uni-
versity of Freiburg and the Department for Psychosomatic Medi-
cine at the Central Institute of Mental Health in Mannheim by 
psychiatrists or general physicians over a period of 2 years (2002–
2004). A majority of the patients contacted the unit to be diag-
nosed and subsequently to participate in an inpatient DBT pro-
gram. Diagnosis was assessed by means of the BPD segments of 
the International Personality Disorder Examination (IPDE). The 
interviews were carried out by trained and experienced clinicians 
(interrater reliability/IPDE: 0.77): 16.1% met 5 DSM-IV criteria, 
20.0% met 6 criteria, 28.4% met 7 criteria, 20.0% met 8 criteria and 
15.5% met 9 criteria. Eight patients were excluded due to frequent 
missing values; thus, 147 patients were included into data analysis 
(age: mean = 29 years, SD = 7.85; range 18–51). The BSL-23 was 
derived from data collected using the BSL-95.
All four studies (referring to samples 1–4) were carried out in 
accordance with the Helsinki Declaration, the Convention of the 
Council of Europe on Human Rights and Biomedicine.
Samples 5a–5e
To test if the BSL-23 discriminates between BPD patients and 
other patient groups, the BSL-95 was administered to patients 
with different axis I disorders and no co-occurring diagnosis of 
BPD (the BSL-23 was derived from data collected using the BSL-
95):
Sample 5a: 84 patients with a major depression (age: mean = 
46 years; range 18–77).
Sample 5b: 51 patients with schizophrenia (age: mean = 35 
years; range 20–65). 
Sample 5c: 48 patients with anxiety disorders (age: mean = 42 
years; range 20–63).
Sample 5d: 56 patients with an attention deficit and hyperac-
tive disorder (age: mean = 35 years; range 20–53).
Sample 5e: 36 patients with a current post-traumatic stress dis-
order, but no co-occurring BPD (age: mean = 39 years; range 20–
53).
All patients were diagnosed according to the criteria of the 
DSM-IV. The patients in samples 5a–5d were recruited at the De-
partment of Psychiatry at the University of Freiburg. The patients 
in sample 5e were recruited at the Central Institute of Mental 
Health in Mannheim.
Sample 6 
To test if the complete short version of the BSL differs from the 
extraction of the BSL-95 regarding internal consistency, we col-
lected data from 35 female BPD patients (diagnosed with the 
IPDE according to the criteria of the DSM-IV). Most of them had 
formerly been diagnosed for treatment or research projects at the 
Central Institute of Mental Health in Mannheim (age: mean = 
30.7 years, range 19–49).
Statistical Analysis
To test psychometric properties, detailed item analyses were 
carried out, including independent t tests and effect size (d) (using 
pooled standard deviations) followed by regression analysis and 
estimates of internal consistency (Cronbach’s ). We examined 
the validity of the BSL-23 through correlation analyses and t tests, 
the test of sensitivity to change by means of one-sample t tests and 
effect size d (using pooled standard deviation). Calculations were 
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made with the full version of the BSL (BSL-95) and the short ver-
sion (BSL-23). High correlations are defined as statistically sig-
nificant values of 10.50.
Development of the Short Version of the BSL
The First Step of the Development
To create a short version with a high ability to discriminate 
BPD patients from other patient groups, items were selected ac-
cording to analyses comparing the BPD sample 1 with two differ-
ent samples of patients with major depression (sample 5a) and 
attention deficit and hyperactive disorder (sample 5d). Each one 
of the original 95 items was analyzed using independent t tests. 
There were 9 items that showed a high ability to discriminate be-
tween BPD patients and the other two patient groups (all t values 
were at least 5.0).
The Second Step of the Development 
In order to achieve a high degree of sensitivity for therapeuti-
cally induced change, effect sizes of the pooled within-group 
comparisons (before and after treatment) were calculated for each 
item in the full version of the BSL (sample 2). A minimum effect 
size d of 0.30 was necessary to consider an item sensitive to change. 
Seventeen items fulfilled this criterion. 
The Third Step of the Development 
Twenty-six items remained after the first two steps of the pro-
cess. In order to further reduce redundancy, regression analyses 
were conducted to select items that did not add additional infor-
mation to the BSL-23. This process was conducted in a stepwise 
manner (i.e. each regression analysis led to the exclusion of the 
item with the highest variance inflation factor according to col-
linearity diagnostics). During this process, 3 items were excluded. 
The remaining 23 items were double-checked for clinical signifi-
cance and considered to be very important in the assessment of 
borderline symptomatology. This resulted in the 23 items selected 
for the short version of the BSL (BSL-23). Nine of these items had 
a high ability to discriminate BPD patients from other patient 
groups and 14 items had a high degree of sensitivity to change. 
To examine the homogeneity of the global score of the BSL-23, 
a principal component analysis was calculated. 
In accordance with the full version of the BSL, all items are 
rated on a 5-step Likert scale (range: 0–4), and the severity of the 
symptoms is assessed with regard to the past week. Moreover, in 
accordance with the BSL-95, the total score of the BSL-23 is cal-
culated by dividing the total sum by the number of valid items, 
i.e. the total score can range from 0.0 to 4.0.
Further Instruments
To evaluate the convergent validity of the BSL, the Beck De-
pression Inventory (BDI) [21] and the SCL-90-R [16] were ap-
plied. 
Results
Factor Analysis
The principal component analysis yielded one domi-
nant factor which accounted for 40.6% of the total vari-
ance. The scree plot of eigenvalues clearly supported the 
dominance of the first unrotated factor and rather sug-
gested the composition of a total score than to divide the 
BSL-23 into several subscales (fig. 1).
Reliability
Initial analyses of the internal consistency of the BSL-
23 were based on 379 BPD patients (sample 1). The BSL-
23 was derived from data collected using the BSL-95. 
These results showed a high internal consistency for the 
BSL-23 with a Cronbach’s  of 0.97.
Cronbach’s  was also calculated based on an addi-
tional sample with 147 BPD patients (sample 4) to evalu-
ate the internal consistency of both the BSL-95 and the 
BSL-23. These results showed high internal consistency 
for both the BSL-95 ( = 0.98) and the BSL-23 ( = 0.94). 
The high internal consistency of the BSL-23 was also con-
firmed in sample 6, where the BSL-23 was used directly 
for the data assessment ( = 0.96).
The analysis of test-retest reliability within 1 week was 
based on sample 3 (assessment 1: mean = 2.18, SD = 0.86; 
assessment 2: mean = 2.05, SD = 0.96). The test-retest re-
liability was high for the BSL-23 (r = 0.82; p ! 0.0001).
Validity
Investigation of convergent validity also provided fa-
vorable results. Positive moderate to high correlations 
were observed between the BSL-23 and depression as 
measured by the BDI (r = 0.83), as well as general severity 
of psychopathology as measured by the SCL-90-R GSI 
(r = 0.48; p ! 0.001). In sample 6, correlations between the 
BSL-23 and BDI (r = 0.87; p ! 0.01), as well as SCL-90-R 
Factor
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 Fig. 1. Eigenvalue scree plot of the principal component analysis 
(n = 379). 
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GSI (r = 0.89; p ! 0.01) were also high. In addition, high 
scores on the BSL-23 were associated with low scores on 
the visual analog scale that measured global well-being 
(r = –0.47; p ! 0.01 in sample 6; for samples 1, 2 and 4 see 
table 1; all p values !0.001).
Table 1 also shows a high intercorrelation between the 
BSL-95 and the BSL-23 in all samples: r = 0.96 (sample 1), 
r = 0.96 (sample 2) and r = 0.96 (sample 4) (all p values 
!0.001).
As shown in table 2, all BSL-23 and BSL-95 scores of 
BPD patients were higher than in patients with different 
axis I diagnoses (samples 5a–5e). After comparing BPD 
patients with other patient groups, the BSL-23 showed a 
numerically higher effect size (mean effect size: 1.13) 
compared with the BSL-95 (mean effect size: 0.96). 
Distribution of BSL-23 Scores in BPD Patients
Floor or ceiling effects would preclude the valid ex-
amination of the severity of BPD and changes in BPD 
symptoms. Figure 2 shows the distribution of the total 
scores of the BSL-23 in 379 BPD patients (sample 1). The 
scores ranged from 0.04 to 3.83; thus, there was no evi-
dence for floor or ceiling effects. The values for skewness 
Table 1. Intercorrelations (Pearson) between the short version (BSL-23) and the full version of the BSL (BSL-95), 
and the visual analog scale for global well-being (VAS), the GSI of the SCL-90-R, and the BDI in 3 samples
Intercorrelations: Sample 1
(n = 379)
Intercorrelations: Sample 2
(n = 63)
Intercorrelations: Sample 4
(n = 147)
BSL-23 BSL-95 BSL-23 BSL-95 BSL-23 BSL-95
BSL-23 1 – 1 – 1 –
BSL-95 0.96* 1 0.96* 1 0.96* 1
VAS –0.69* –0.73* –0.66* –0.67* –0.63* –0.58*
GSI – – 0.48* 0.47* – –
BDI – – 0.83* 0.82* – –
* p < 0.001.
Table 2. Analyzing the ability of the BSL-23 and the BSL-95 to 
distinguish between patient groups by comparison of patients 
with BPD and patients with axis I disorders (between-group com-
parison pooled effect size)
Samples BSL-23 BSL-951 Effect size
BSL-23
Effect size
BSL-95
BPD (n = 379) 2.0580.90 2.0080.76 – –
ADHD (n = 56) 1.0280.78 1.1980.72 1.22 1.09
Sch (n = 51) 0.9280.53 1.0481.15 1.53 0.98
MD (n = 84) 1.3880.83 1.4480.76 0.77 0.74
Anxiety (n = 48) 1.0980.62 1.1681.18 1.24 0.85
PTSD (n = 36) 1.1980.63 1.2780.52 0.87 1.12
ADHD = Attention deficit hyperactive disorder; Sch = schizo-
phrenia; MD = major depression; PTSD = post-traumatic stress 
disorder. 
1 With the exception of the effect size, these results for the pa-
tients with BPD, schizophrenia, major depression and anxiety 
have been reported in more detail in a previous article [11]. 4.002.00
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 Fig. 2. Distribution of BSL-23 total scores in a sample of 379 BPD 
patients. 
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(–0.27) and kurtosis (–0.83) were within an acceptable 
range. Similar results were found in sample 6: the scores 
ranged from 0.35 to 3.87 and the values for skewness and 
kurtosis were –0.39 and –1.01, respectively.
Sensitivity to Change
To measure sensitivity to change, the BSL-95 was ad-
ministered before treatment and after 12 weeks of DBT 
twice to 63 female BPD patients (sample 2) [18, 19]. The 
BSL-23 was derived from data collected using the BSL-95. 
Table 3 shows that the BSL-23 scores significantly im-
proved from pre- to post-treatment assessment. The ef-
fect sizes were numerically larger for the BSL-23 than for 
the BSL-95.
Discussion
The aim of this study was to develop and evaluate a 
short version of the BSL. Twenty-three items that displayed 
a high level of sensitivity to change and a high ability to 
discriminate BPD patients from other psychiatric patients 
were selected from the item pool of the full version of the 
BSL-95. In the evaluation of the psychometric properties 
of the short version (BSL-23), the BSL-23 items were par-
tially derived from data collected using the full version 
(BSL-95). The principal component analysis strongly sug-
gested the composition of a global score. The results 
showed that the BSL-23 has excellent internal consistency 
and good test-retest reliability. The analyses of validity 
also yielded favorable results. Initial analyses showed that 
the BSL-23 is sensitive to change after treatment. 
Findings from this study indicated that the BSL-23 has 
strong reliability, similar to that of the BSL-95. The  co-
efficient of 0.97 for the BSL-23 is similar to that reported 
for the BSL-95 (0.97) [11]. Similarly, high internal consis-
tency was apparent within a new sample of 147 female 
BPD patients. The test-retest reliability for a 1-week pe-
riod was also high (r = 0.82) and similar in magnitude to 
that of the BSL-95 [11].
Findings from the present study also supported the 
convergent validity of the BSL-23 as the correlations of 
the BSL-23 with structurally related scales were moderate 
to high. As anticipated, the correlation of the BSL-23 with 
a measure of global well-being was high and negative in 
both samples. In addition, the intercorrelation between 
the BSL-95 and BSL-23 was extremely high in both the 
sample of 379 BPD patients and in the sample of 147 fe-
male BPD patients.
BPD patients had higher BSL-23 scores in comparison 
with other patient groups (samples 5a–5e). This result is 
consistent with previous results on the BSL-95 [11]. As 
many of the items of the BSL-23 had been selected be-
cause of their high ability to discriminate between BPD 
patients and other patient groups with different axis I di-
agnoses, it was not surprising that the BSL-23 showed a 
numerically higher effect size d (between-group compar-
isons; mean effect size: 1.13) compared with the BSL-95 
(mean effect size: 0.96). Interestingly, the BSL-23 dis-
criminated between BPD patients and patients with a 
post-traumatic stress disorder, even though these pa-
tients show many similarities in symptoms. In addition, 
all results in our previous paper on the psychometric 
properties of the BSL-95 [11] based on sample 1 (n = 379) 
were confirmed by the results based on a new sample 
(sample 4) with 147 BPD patients and in a sample of 35 
female BPD patients directly using the BSL-23 (sam-
ple 6).
The preliminary data on the sensitivity to change also 
showed good results. In the course of a 12-week disorder-
specific treatment of BPD, the BSL-23 indicated signifi-
cant improvements in the symptomatology (d = 0.47). 
This effect size was numerically larger than the effect size 
for the BSL-95 (d = 0.38). Again, this result was expected, 
as the items were partially selected for sensitivity to 
change. Thus, this promising result regarding sensitivity 
to change warrants replication in a new study.
In sum, data suggest that the BSL-23 has good to excel-
lent psychometric properties. The results are consistent 
with those of the BSL-95. In particular, the BSL-23 dis-
criminates BPD patients from other patient groups and 
shows a moderate level of sensitivity to change. The 
BSL-23 is a brief, efficient measure of borderline-typical 
symptomatology that can limit the patient burden and 
the assessment time.
In the present article, the BSL-23 was partially devel-
oped from data collected using the BSL-95 (samples 1–5). 
Table 3. Comparison of the BSL scores before and after treatment 
(t tests) (n = 64)
Before 
treatment
After 
treatment
t test d.f. p Effect 
size, d
BSL-23 2.2580.85 1.8280.99 3.94 63 0.0001 0.47
BSL-951 2.0980.68 1.8080.82 3.14 63 0.003 0.38
1 With the exception of the effect size, these results have been 
reported in more detail in a previous article [11].
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Therefore, it is important to continue the evaluation of 
the BSL-23 using data from other independent samples 
assessed directly with the BSL-23. Future research should 
also investigate the possibility to use the BSL-95 and the 
BSL-23 as a screening instrument. Along these lines, fu-
ture studies might examine the diagnostic efficiency 
(sensitivity, specificity, positive and negative predictive 
power) of BSL-23 scores when referenced to diagnoses of 
BPD. 
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Appendix 1. Borderline Symptom List: Short Version (BSL-23)
Name/Code: …………………………………………………………………………..                       Date: ………………………………….……
Please follow these instructions when answering the questionnaire: In the following table you will find a set of difficulties and prob-
lems which possibly describe you. Please work through the questionnaire and decide how much you suffered from each problem in 
the course of the last week. In case you have no feelings at all at the present moment, please answer according to how you think you 
might have felt. Please answer honestly. All questions refer to the last week. If you felt different ways at different times in the week, give 
a rating for how things were for you on average. Please be sure to answer each question. 
In the course of last week... not at all a little rather much very strong
1 It was hard for me to concentrate 0 1 2 3 4
2 I felt helpless 0 1 2 3 4
3 I was absent-minded and unable to remember what I was actually doing 0 1 2 3 4
4 I felt disgust 0 1 2 3 4
5 I thought of hurting myself 0 1 2 3 4
6 I didn’t trust other people 0 1 2 3 4
7 I didn’t believe in my right to live 0 1 2 3 4
8 I was lonely 0 1 2 3 4
9 I experienced stressful inner tension 0 1 2 3 4
10 I had images that I was very much afraid of 0 1 2 3 4
11 I hated myself 0 1 2 3 4
12 I wanted to punish myself 0 1 2 3 4
13 I suffered from shame 0 1 2 3 4
14 My mood rapidly cycled in terms of anxiety, anger, and depression 0 1 2 3 4
15 I suffered from voices and noises from inside and/or outside my head 0 1 2 3 4
16 Criticism had a devastating effect on me 0 1 2 3 4
17 I felt vulnerable 0 1 2 3 4
18 The idea of death had a certain fascination for me 0 1 2 3 4
19 Everything seemed senseless to me 0 1 2 3 4
20 I was afraid of losing control 0 1 2 3 4
21 I felt disgusted by myself 0 1 2 3 4
22 I felt as if I was far away from myself 0 1 2 3 4
23 I felt worthless 0 1 2 3 4
Now we would like to know in addition the quality of your overall personal state in the course of the last week. 0% means abso-
lutely down, 100% means excellent. Please check the percentage which comes closest.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
(very bad) J K (excellent)
Please double-check for missing answers
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